The other approved drugs for T2D include DPP-4 inhibitors, Sulfonylureas, and Meglitinides, whose treatment generally increases insulin secretion and/or glucose utilization19,20, in addition to exogenous insulin application to effectively ameliorate hyperglycemia and also improve the insulin response in target tissues, but owes limitations of short-term duration. This evidence concerns the gene INS and Hyperglycemia.